Aprea Therapeutics Boosts Cancer Drug Patents With Long-Term IP Protection

Aprea Therapeutics, a biopharmaceutical company, has shared information regarding its intellectual property related to two main cancer treatment initiatives. The drug ATRN-119 functions as an ATR inhibitor within their program while undergoing clinical testing in ABOYA-119 for the treatment of advanced solid tumours that exhibit DDR-related gene mutations. The candidate benefits from four United States patents as well as multiple pending patent applications, which, when combined, provide worldwide protection until 2035-2037 and possibly extend to 2044 through new grants. Further regulatory exclusivity can increase protection by 5 years. 

Oren Gilad, PhD, President and Chief Executive Officer of Aprea, commented, “Our strong patent portfolio reflects our commitment to innovation and leadership in DNA Damage Response therapeutics. Intellectual property is an essential component of Aprea’s strategy, enabling us to advance first-in-class and best-in-class oncology treatments while protecting the value of our assets. Our commitment to securing global intellectual property rights underscores our long-term vision to develop and commercialize breakthrough therapies for difficult-to-treat cancers.”   

Meanwhile, Aprea’s WEE1 kinase inhibitor program, led by APR-1051, which is under evaluation in the ACESOT-1051 Phase 1 trial for tumours with specific gene alterations, has pending patent applications in the U.S. and internationally, with potential coverage until 2043, excluding regulatory extensions. Both portfolios cover proprietary compounds, drug compositions, and usage methods, strengthening Aprea's position in targeted cancer therapies.